The subgroups of HER2-positive breast cancer patients numerically increase in the course of disease (HER2-positive: 21.1–22.0% − 31.8%), whereas the HER2-negative cohort decreases correspondingly. The gene discussed is ERBB2; the disease is breast cancer.